Efficacy of sotrovimab for persistent coronavirus disease-2019 in a severely immunocompromised person living with HIV

Montejano, Rocío; Marcelo, Cristina; Falces‐Romero, Iker; Valle, Luis González del; Soto, Teresa De; García-Rodríguez, Julio; Arribas, José Ramón

doi:10.1097/qad.0000000000003179

Cited by 9 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Case # Authors Age,Sex Immunosuppression Persistence Elimination Rx attempted Anti-SARS CoV-2 Abs detected? Virologic outcome Mortality Primary disease Secondary causes Virologic duration Clinical symptoms 1 Baang et al, 2021 , Baang et al, 2021 60 M MCL CD20 bispecific Ab + 2nd B-cell directed Ab, as part of chemotherapy regimen 131 days Cough, Dyspnoea, Fever RDV + CP (x2) Minimally post-CP, otherwise negative Likely cleared (unstated) No 2 Montejano et al, 2022 , Montejano et al, 2022 30 M HIV + DLBCL Anti-CD20-containing chemotherapy (RIX) CAR- T -cell therapy 97 days Fever, “pulmonary infiltrates“ RDV + CP, mAb (Sotrovimab) N/A Cleared No 3 Morel et al , 2022 ( Morel et al, 2022 ) 74 M SOT (renal) ITP Tacrolimus, MMF, steroidsRIX (2 m pre-COVID) 3 months Dyspnoea, Fever, hypoxia – N/A Cleared No 4 Ko et al ., 2022 ( Ko et al, 2022 ) 53 M AML GvHD Allogenic SCT Ruxolitinib + steroids 94 days Cough, fever, dyspnoea, RDV (x3), Cas/Imd N/A Persisted No 5 Ko et al ., 2022 ( Ko et al, 2022 ) 67 F …”

Section: Resultsmentioning

confidence: 99%

Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review

Hettle

Hutchings²,

Muir³

et al. 2022

Clinical Infection in Practice

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review

Hettle

Hutchings²,

Muir³

et al. 2022

Clinical Infection in Practice

View full text Add to dashboard Cite

“…Even worse, it has been demonstrated that in immunocompromised patients undergoing treatment with sotrovimab, treatment failure was associated with emerging spike mutations conferring resistance to sotrovimab [ 115 ]. On the other hand, two case reports suggested that the use of sotrovimab as an adjunctive to remdesivir therapy in severely immunocompromised AIDS patients showed a dramatic improvement in symptoms and rapid viral clearance [ 116 , 117 ].…”

Section: Management Of Covid-19 In Pwhmentioning

confidence: 99%

HIV and COVID-19 Co-Infection: Epidemiology, Clinical Characteristics, and Treatment

Basoulis

Mastrogianni

Voutsinas

et al. 2023

Viruses

View full text Add to dashboard Cite

The COVID-19 pandemic has been a global medical emergency with a significant socio-economic impact. People with HIV (PWH), due to the underlying immunosuppression and the particularities of HIV stigma, are considered a vulnerable population at high risk. In this review, we report what is currently known in the available literature with regards to the clinical implications of the overlap of the two epidemics. PWH share the same risk factors for severe COVID-19 as the general population (age, comorbidities), but virological and immunological status also plays an important role. Clinical presentation does not differ significantly, but there are some opportunistic infections that can mimic or co-exist with COVID-19. PWH should be prime candidates for preventative COVID-19 treatments when they are available, but in the setting of resistant strains, this might be not easy. When considering small-molecule medications, physicians need to always remember to address potential interactions with ART, and when considering immunosuppressants, they need to be aware of potential risks for opportunistic infections. COVID-19 shares similarities with HIV in how the public perceives patients—with fear of the unknown and prejudice. There are opportunities for HIV treatment hidden in COVID-19 research with the leaps gained in both monoclonal antibody and vaccine development.

show abstract

“…Another approach for the management of suspected protracted SARS-CoV-2 infection is the use of monoclonal antibodies (mAb). In some cases, treatment courses of RDV and/ or CP failed to clear the virus, resulting in the use of different mAb such as sotrovimab [54]and casirivimab/imdevimab [26,55,56]. There have been reports of bamlanivimab use, but rapid development of resistance did not allow further use as monotherapy [25,28,33,57].…”

Section: Monoclonal Antibodiesmentioning

confidence: 99%

Immunocompromised Patients with Protracted COVID-19: a Review of “Long Persisters”

2022

View full text Add to dashboard Cite

Purpose of Review Certain immunocompromised individuals are at risk for protracted COVID-19, in which SARS-CoV-2 leads to a chronic viral infection. However, the pathogenesis, diagnosis, and management of this phenomenon remain ill-defined. Recent Findings Herein, we review key aspects of protracted SARS-CoV-2 infection in immunocompromised individuals, or the so-called long persisters, and describe the clinical presentation, risk factors, diagnosis, and treatment modalities of this condition, as well as intra-host viral evolution. Based on the available data, we also propose a framework of criteria with which to approach this syndrome. Summary Protracted COVID-19 is an uncharacterized syndrome affecting patients with B-cell depletion; our proposed diagnostic approach and definitions will inform much needed future research.

show abstract

Efficacy of sotrovimab for persistent coronavirus disease-2019 in a severely immunocompromised person living with HIV

Cited by 9 publications

References 9 publications

Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review

Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review

HIV and COVID-19 Co-Infection: Epidemiology, Clinical Characteristics, and Treatment

Immunocompromised Patients with Protracted COVID-19: a Review of “Long Persisters”

Contact Info

Product

Resources

About